Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 134

1.

Cholinergic Potentiation Alters Perceptual Eye Dominance Plasticity Induced by a Few Hours of Monocular Patching in Adults.

Sheynin Y, Chamoun M, Baldwin AS, Rosa-Neto P, Hess RF, Vaucher E.

Front Neurosci. 2019 Jan 31;13:22. doi: 10.3389/fnins.2019.00022. eCollection 2019.

2.

Part 1: Introduction to Machine Learning in the Nuclear Medicine Context.

Uribe CF, Mathotaarachchi S, Gaudet VC, Smith KC, Rosa-Neto P, Benard F, Black SE, Zukotynski K.

J Nucl Med. 2019 Feb 7. pii: jnumed.118.223495. doi: 10.2967/jnumed.118.223495. [Epub ahead of print]

PMID:
30733322
3.

Constrained instruments and their application to Mendelian randomization with pleiotropy.

Jiang L, Oualkacha K, Didelez V, Ciampi A, Rosa-Neto P, Benedet AL, Mathotaarachchi S, Richards JB, Greenwood CMT; and for the Alzheimer’s Disease Neuroimaging Initiative.

Genet Epidemiol. 2019 Jan 12. doi: 10.1002/gepi.22184. [Epub ahead of print]

PMID:
30635941
4.

Astrocyte Biomarkers in Alzheimer's Disease.

Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER.

Trends Mol Med. 2019 Feb;25(2):77-95. doi: 10.1016/j.molmed.2018.11.006. Epub 2019 Jan 2. Review.

PMID:
30611668
5.

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging.

Schirrmacher R, Bailey JJ, Mossine AV, Scott PJH, Kaiser L, Bartenstein P, Lindner S, Kaplan DR, Kostikov A, Fricker G, Mahringer A, Rosa-Neto P, Schirrmacher E, Wängler C, Wängler B, Thiel A, Soucy JP, Bernard-Gauthier V.

Pharmaceuticals (Basel). 2019 Jan 3;12(1). pii: E7. doi: 10.3390/ph12010007. Review.

6.

In vivo metabotropic glutamate receptor type 5 abnormalities localize the epileptogenic zone in mesial temporal lobe epilepsy.

Lam J, DuBois JM, Rowley J, González-Otárula KA, Soucy JP, Massarweh G, Hall JA, Guiot MC, Rosa-Neto P, Kobayashi E.

Ann Neurol. 2019 Feb;85(2):218-228. doi: 10.1002/ana.25404. Epub 2019 Jan 20.

PMID:
30597619
7.

A simplified radiosynthesis of [18 F]MK-6240 for tau PET imaging.

Hopewell R, Ross K, Kostikov A, Pascoal TA, Alberti T, Lacatus-Samoila M, Soucy JP, Bennacef I, Kobayashi E, Kang MS, Rosa-Neto P, Massarweh G.

J Labelled Comp Radiopharm. 2019 Feb;62(2):109-114. doi: 10.1002/jlcr.3695. Epub 2018 Dec 19.

PMID:
30426529
8.

Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.

Schilling LP, Pascoal TA, Zimmer ER, Mathotaarachchi S, Shin M, de Mello Rieder CR, Gauthier S, Palmini A, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurobiol. 2018 Nov 9. doi: 10.1007/s12035-018-1405-1. [Epub ahead of print]

PMID:
30414086
9.

Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease.

Zhang H, Ng KP, Therriault J, Kang MS, Pascoal TA, Rosa-Neto P, Gauthier S; Alzheimer’s Disease Neuroimaging Initiative.

Transl Neurodegener. 2018 Sep 10;7:23. doi: 10.1186/s40035-018-0127-7. eCollection 2018.

10.

The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia.

Ng KP, Chiew HJ, Lim L, Rosa-Neto P, Kandiah N, Gauthier S.

Expert Rev Neurother. 2018 Nov;18(11):859-869. doi: 10.1080/14737175.2018.1532792. Epub 2018 Oct 10.

PMID:
30286681
11.

Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.

Zhang H, Therriault J, Kang MS, Ng KP, Pascoal TA, Rosa-Neto P, Gauthier S; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2018 Aug 16;10(1):80. doi: 10.1186/s13195-018-0407-6.

12.

Optimal use of cholinergic drugs in Alzheimer's disease.

Gauthier S, Herrmann N, Rosa-Neto P.

Brain. 2018 Sep 1;141(9):e68. doi: 10.1093/brain/awy204. No abstract available.

PMID:
30084978
13.

In vivo quantification of neurofibrillary tangles with [18F]MK-6240.

Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, Bennacef I, Therriault J, Ng KP, Hopewell R, Bouhachi R, Hsiao HH, Benedet AL, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P.

Alzheimers Res Ther. 2018 Jul 31;10(1):74. doi: 10.1186/s13195-018-0402-y.

14.

Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress.

Guadagno A, Kang MS, Devenyi GA, Mathieu AP, Rosa-Neto P, Chakravarty M, Walker CD.

Brain Struct Funct. 2018 Nov;223(8):3711-3729. doi: 10.1007/s00429-018-1720-3. Epub 2018 Jul 21.

PMID:
30032360
15.

PET/CT of Dementia.

Zukotynski K, Kuo PH, Mikulis D, Rosa-Neto P, Strafella AP, Subramaniam RM, Black SE.

AJR Am J Roentgenol. 2018 Aug;211(2):246-259. doi: 10.2214/AJR.18.19822. Epub 2018 Jun 27.

PMID:
29949415
16.

Test-retest variability of [11 C]ABP688 estimates of metabotropic glutamate receptor subtype 5 availability in humans.

Smart K, Cox SML, Nagano-Saito A, Rosa-Neto P, Leyton M, Benkelfat C.

Synapse. 2018 Sep;72(9):e22041. doi: 10.1002/syn.22041. Epub 2018 Jul 20.

PMID:
29935121
17.

Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?

Gauthier S, Zhang H, Ng KP, Pascoal TA, Rosa-Neto P.

Transl Neurodegener. 2018 May 31;7:12. doi: 10.1186/s40035-018-0117-9. eCollection 2018. Review.

18.

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.

Meyer PF, Savard M, Poirier J, Labonté A, Rosa-Neto P, Weitz TM, Town T, Breitner J; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group.

J Alzheimers Dis. 2018;63(2):577-590. doi: 10.3233/JAD-170887.

19.

Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.

Gauthier S, Ng KP, Pascoal TA, Zhang H, Rosa-Neto P.

J Alzheimers Dis. 2018;64(s1):S23-S31. doi: 10.3233/JAD-179924.

20.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

PMID:
29482212

Supplemental Content

Loading ...
Support Center